肝动脉灌注化疗(HAIC)治疗肝细胞癌(HCC)的研究进展

Research advances in the treatment of hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma (HCC)

肝动脉化疗栓塞、分子靶向治疗和免疫治疗是目前晚期肝细胞癌(hepatocellular carcinoma,HCC)的推荐治疗方法,但尚缺乏治疗无效或失败后的补救治疗。晚期HCC患者接受肝动脉灌注化疗(hepatic arterial infusion chemotherapy,HAIC)有生存获益,提示HAIC可能是各种肝癌治疗无效或失败后的一种补救治疗方法。尽管既往研究表明HAIC对晚期HCC治疗有效,但是缺少大样本随机对照临床试验的数据。为了使HAIC成为晚期HCC推荐治疗方法,须将HAIC与其他标准治疗方法进行比较;寻找对HAIC治疗有反应的预测指标,优化和统一HAIC治疗方案等。本综述旨在提供HAIC临床应用的研究进展。

Hepatic arterial chemoembolization,molecular targeted therapy and immunotherapy are currently recommended treatments for advanced hepatocellular carcinoma(HCC).However,there is a lack of remedial treatment after these treatments are ineffective or failed.Some studies have found that hepatic artery infusion chemotherapy(HAIC)has a survival benefit in patients with advanced HCC,suggesting that HAIC may be a salvage treatment for the failure or ineffectiveness of various treatments.Although previous studies have shown that HAIC is effective in the treatment of advanced HCC,data from large randomized controlled clinical trials are missing.In order to make HAIC as a recommended treatment for advanced HCC,much more work needs to be done:HAIC to be compared with current standard treatments for advanced HCC;to delineate predictive indicators for efficacy of HAIC;to optimize and standardize HAIC treatment.This review aims to provide an introduction of the research progresses in clinical applications of HAIC treatment.